NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Novavax's COVID-19 vaccine is over 90% effective, firm says
    Novavax's COVID-19 vaccine is over 90% effective, firm says
    India

    Novavax's COVID-19 vaccine is over 90% effective, firm says

    Written by Sagar
    June 14, 2021 | 07:42 pm 3 min read
    Novavax's COVID-19 vaccine is over 90% effective, firm says
    Novavax's coronavirus vaccine has been found safe and over 90% effective.

    American firm Novavax's coronavirus vaccine has been found safe and over 90% effective, including against some variants, the company announced on Monday. The results are from a phase-three clinical trial of nearly 30,000 participants conducted at 119 sites across the United States and Mexico. The jab will be a fourth vaccine option for the US after vaccines from Pfizer, Moderna, and Johnson & Johnson.

    Jab provides 100% protection from moderate/severe disease

    In a statement issued today, the company said the vaccine provides 100% protection from moderate or severe disease of COVID-19 and 90% protection overall. It also has a 93% efficacy against "predominantly circulating Variants of Concern and Variants of Interest." "Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial," the company tweeted today.

    Here is the tweet by Novavax

    NEW DATA RELEASE: Novavax #COVID19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial https://t.co/lIOiQXxDtD pic.twitter.com/4ePHxDpziZ

    — Novavax (@Novavax) June 14, 2021

    Company to apply for approval in 3rd quarter of year

    The Maryland-based company has said that it intends to apply for regulatory approval from the US Food and Drug Administration (FDA) in the third quarter of 2021 or September. The firm also said it is on track to take the production capacity to 100 million (10 crore) doses per month and 150 million (15 crore) doses by the end of this year.

    'One step closer,' says company's chief executive

    "Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines," said company president and CEO Stanley Erck. "Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines."

    In India, vaccine will be manufactured by the Serum Institute

    A special benefit offered by the Novavax vacccine - formally called NVX-CoV2373 - is it does not need to be stored at ultra-low temperatures. The company says it can be stored at 2-8 degree Celsius - implying it would be easier to transport. In India, the jab will be manufactured by the Pune-based Serum Institute of India, which already makes the Oxford-AstraZeneca vaccine.

    US has plenty options. So, where will this jab go?

    Given the US has already provided a coronavirus vaccine shot to over half its population and has enough stocks for the rest, the Novavax vaccine would be needed more elsewhere. In fact, many African nations have vaccinated less than 1% of their populations while India, which faced the world's worst coronavirus outbreak earlier this year, has vaccinated just 3.4% of its total population.

    Novavax also applying in India, Britain, and EU

    Novavax is also reportedly applying in Britain, the European Union, India, and South Korea. Erck, the company executive, said in an interview Novavax would probably get its first authorization somewhere outside the US.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Vaccine
    Coronavirus
    COVID-19

    Vaccine

    4L COVID-19 vaccine doses to reach states in 3 days Ministry of Health and Family Welfare
    Centre considers using drones to deliver vaccines in tricky terrains Drones
    After updating vaccine policy, Centre may renegotiate Covishield, COVAXIN prices COVAXIN
    India must increase vaccinations five-fold to reach 100% target: Report India

    Coronavirus

    Pune-based start-up develops mask that inactivates novel coronavirus Startups
    Nine arrested for burning Bhaichung Bhutia's effigy in Sikkim Sikkim
    Centre is setting up fifty 100-bed modular hospitals across India India
    Coronavirus: India records lowest single-day spike in 74 days Ministry of Health and Family Welfare

    COVID-19

    How does India plan to vaccinate children against coronavirus? India
    US earmarks billions for chip production as COVID-19 hits Taiwan Taiwan
    Private hospitals used only 17% COVID-19 vaccine doses in May India
    COVID-19: DCGI gives approval for phase-2 clinical trials of Colchicine Health & Wellness
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023